WO2010026168A3 - Substances et procédés pour le traitement de la sclérose en plaques véhiculée par les lymphocytes b - Google Patents
Substances et procédés pour le traitement de la sclérose en plaques véhiculée par les lymphocytes b Download PDFInfo
- Publication number
- WO2010026168A3 WO2010026168A3 PCT/EP2009/061359 EP2009061359W WO2010026168A3 WO 2010026168 A3 WO2010026168 A3 WO 2010026168A3 EP 2009061359 W EP2009061359 W EP 2009061359W WO 2010026168 A3 WO2010026168 A3 WO 2010026168A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- multiple sclerosis
- cell mediated
- gamma receptor
- treatment
- mediated multiple
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Transplantation (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2735085A CA2735085C (fr) | 2008-09-05 | 2009-09-02 | Recepteur fc gamma iib destine au traitement de sclerose en plaque mediee par cellule beta |
ES09782523T ES2386335T3 (es) | 2008-09-05 | 2009-09-02 | Receptor Fc-gamma para el tratamiento de la esclerosis múltiple mediada por los linfocitos B |
JP2011525541A JP5519674B2 (ja) | 2008-09-05 | 2009-09-02 | B細胞媒介性多発性硬化症の治療のための物質および方法 |
RU2011112857/15A RU2522251C2 (ru) | 2008-09-05 | 2009-09-02 | Вещества и способы лечения рассеянного склероза, опосредованного в клетками |
AU2009289280A AU2009289280C1 (en) | 2008-09-05 | 2009-09-02 | FC gamma receptor for the treatment of B cell mediated multiple sclerosis |
US13/062,115 US20110230391A1 (en) | 2008-09-05 | 2009-09-02 | Fc gamma receptor for the treatment of b cell mediated multiple sclerosis |
EP09782523A EP2331114B1 (fr) | 2008-09-05 | 2009-09-02 | Recepteur fc-gamma pour le traitement de la sclérose en plaques médiée par les lymphocytes b |
NZ591140A NZ591140A (en) | 2008-09-05 | 2009-09-02 | Fc gamma receptor for the treatment of b cell mediated multiple sclerosis |
US13/912,859 US20130303458A1 (en) | 2008-09-05 | 2013-06-07 | Substances and methods for the treatment of b cell mediated multiple sclerosis |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP08163800.9 | 2008-09-05 | ||
EP08163800A EP2161031A1 (fr) | 2008-09-05 | 2008-09-05 | Recepteur Fc-gamma pour le traitement de la sclérose en plaques médiée par les lymphocytes B |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/062,115 A-371-Of-International US20110230391A1 (en) | 2008-09-05 | 2009-09-02 | Fc gamma receptor for the treatment of b cell mediated multiple sclerosis |
US13/912,859 Division US20130303458A1 (en) | 2008-09-05 | 2013-06-07 | Substances and methods for the treatment of b cell mediated multiple sclerosis |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2010026168A2 WO2010026168A2 (fr) | 2010-03-11 |
WO2010026168A3 true WO2010026168A3 (fr) | 2010-05-27 |
Family
ID=40227712
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2009/061359 WO2010026168A2 (fr) | 2008-09-05 | 2009-09-02 | Substances et procédés pour le traitement de la sclérose en plaques véhiculée par les lymphocytes b |
Country Status (9)
Country | Link |
---|---|
US (2) | US20110230391A1 (fr) |
EP (2) | EP2161031A1 (fr) |
JP (1) | JP5519674B2 (fr) |
AU (1) | AU2009289280C1 (fr) |
CA (1) | CA2735085C (fr) |
ES (1) | ES2386335T3 (fr) |
NZ (1) | NZ591140A (fr) |
RU (1) | RU2522251C2 (fr) |
WO (1) | WO2010026168A2 (fr) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20130108619A1 (en) * | 2011-11-02 | 2013-05-02 | Isaac Melamed | Intravenous immunoglobulin processing, diagnostic, and treatment systems and methods |
EP2796144A1 (fr) * | 2013-04-26 | 2014-10-29 | SuppreMol GmbH | Formulations hautement concentrées de récepteurs Fc solubles |
CA2927263C (fr) * | 2013-10-16 | 2022-12-13 | Suppremol Gmbh | Recepteur soluble de fc gamma pour le traitement de maladies bulleuses auto-immunes |
MX2016013686A (es) * | 2014-04-18 | 2017-03-31 | Univ New York State Res Found | Anticuerpos de antigeno anti-tf humanizado. |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050175998A1 (en) * | 2001-07-30 | 2005-08-11 | Jin Nakahara | Medicinal compositions containing fc receptor gamma-chain activator |
WO2008091682A2 (fr) * | 2007-01-23 | 2008-07-31 | Zymogenetics, Inc. | FCγRIA SOLUBLE ET MÉTHODES ASSOCIÉES |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU646822B2 (en) | 1989-10-13 | 1994-03-10 | Kirin-Amgen Inc. | Erythropoietin isoforms |
US6552170B1 (en) * | 1990-04-06 | 2003-04-22 | Amgen Inc. | PEGylation reagents and compounds formed therewith |
JPH06117187A (ja) | 1992-10-08 | 1994-04-26 | Iseki Tory Tech Inc | シールド掘削機 |
AU2346900A (en) | 1998-11-30 | 2000-06-19 | Eli Lilly And Company | Erythropoietic compounds |
EP1006183A1 (fr) * | 1998-12-03 | 2000-06-07 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Récepteurs Fc recombinantes et solubles |
PE20010288A1 (es) | 1999-07-02 | 2001-03-07 | Hoffmann La Roche | Derivados de eritropoyetina |
EP1961425B1 (fr) | 2000-04-21 | 2017-07-19 | Amgen Inc. | Procédés et analogues de l'érytropoïétine pour la prévention et le traitement de l'anémie |
WO2001082774A2 (fr) * | 2000-04-21 | 2001-11-08 | Rutgers, The State University Of New Jersey | Procedes et compositions destines au diagnostic de la schizophrenie |
US6930086B2 (en) | 2001-09-25 | 2005-08-16 | Hoffmann-La Roche Inc. | Diglycosylated erythropoietin |
CN1882355A (zh) | 2003-09-09 | 2006-12-20 | 沃伦药品公司 | 保持内源性***组织保护活性的长效*** |
ZA200701783B (en) * | 2004-09-02 | 2009-10-28 | Genentech Inc | Anti-Fc-gamma RIIB receptor antibody and uses therefor |
EP1870422A1 (fr) * | 2006-06-20 | 2007-12-26 | SuppreMol GmbH | Moyens pour le traitement de maladies caractérisées par une réaction immunitaire excessive |
WO2008021290A2 (fr) * | 2006-08-09 | 2008-02-21 | Homestead Clinical Corporation | Protéines spécifiques d'organes et procédés d'utilisation |
-
2008
- 2008-09-05 EP EP08163800A patent/EP2161031A1/fr not_active Ceased
-
2009
- 2009-09-02 WO PCT/EP2009/061359 patent/WO2010026168A2/fr active Application Filing
- 2009-09-02 JP JP2011525541A patent/JP5519674B2/ja not_active Expired - Fee Related
- 2009-09-02 US US13/062,115 patent/US20110230391A1/en not_active Abandoned
- 2009-09-02 RU RU2011112857/15A patent/RU2522251C2/ru active
- 2009-09-02 EP EP09782523A patent/EP2331114B1/fr not_active Not-in-force
- 2009-09-02 NZ NZ591140A patent/NZ591140A/xx not_active IP Right Cessation
- 2009-09-02 CA CA2735085A patent/CA2735085C/fr not_active Expired - Fee Related
- 2009-09-02 ES ES09782523T patent/ES2386335T3/es active Active
- 2009-09-02 AU AU2009289280A patent/AU2009289280C1/en not_active Ceased
-
2013
- 2013-06-07 US US13/912,859 patent/US20130303458A1/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050175998A1 (en) * | 2001-07-30 | 2005-08-11 | Jin Nakahara | Medicinal compositions containing fc receptor gamma-chain activator |
WO2008091682A2 (fr) * | 2007-01-23 | 2008-07-31 | Zymogenetics, Inc. | FCγRIA SOLUBLE ET MÉTHODES ASSOCIÉES |
Non-Patent Citations (2)
Title |
---|
SCHAEFER B ET AL: "Sa.31. Targeting Fcgamma Receptors in the Treatment of Multiple Sclerosis", CLINICAL IMMUNOLOGY, ACADEMIC PRESS, US, vol. 119, 1 January 2006 (2006-01-01), pages S115 - S116, XP024911490, ISSN: 1521-6616, [retrieved on 20060101] * |
TORKILDSEN O; VEDELER C A; NYLAND H I; MYHR K -M: "Fc gamma R and multiple sclerosis: an overview", ACTA NEUROLOGICA SCANDINAVICA, vol. 113, no. Suppl. 183, 2006, pages 61 - 63, XP009110961, ISSN: 0001-6314 * |
Also Published As
Publication number | Publication date |
---|---|
ES2386335T3 (es) | 2012-08-17 |
AU2009289280B2 (en) | 2014-05-29 |
US20130303458A1 (en) | 2013-11-14 |
CA2735085A1 (fr) | 2010-03-11 |
EP2161031A1 (fr) | 2010-03-10 |
AU2009289280C1 (en) | 2014-10-02 |
AU2009289280B8 (en) | 2014-06-12 |
RU2011112857A (ru) | 2012-10-10 |
JP2012502000A (ja) | 2012-01-26 |
US20110230391A1 (en) | 2011-09-22 |
CA2735085C (fr) | 2018-10-16 |
NZ591140A (en) | 2012-10-26 |
AU2009289280A1 (en) | 2010-03-11 |
RU2522251C2 (ru) | 2014-07-10 |
EP2331114B1 (fr) | 2012-05-16 |
JP5519674B2 (ja) | 2014-06-11 |
AU2009289280A8 (en) | 2014-06-12 |
EP2331114A2 (fr) | 2011-06-15 |
WO2010026168A2 (fr) | 2010-03-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2011103202A3 (fr) | Modulateurs du récepteur des androgènes et leurs utilisations | |
WO2010132882A3 (fr) | Compositions sublinguales de dexmédétomidine et leurs procédés d'utilisation | |
WO2012024620A3 (fr) | Inhibiteurs de l'autotaxine et leurs utilisations | |
WO2012037411A3 (fr) | Modulateurs des récepteurs des oestrogènes et leurs utilisations | |
WO2011156518A3 (fr) | Modulateur du récepteur oestrogénique et utilisation de ces derniers | |
GEP20135724B (en) | Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for treatment or prevention of diabetes | |
MX2011011854A (es) | Dihidropirimidinonas para uso como inhibidores de la bace2. | |
WO2010008831A3 (fr) | Composés et procédés pour moduler les récepteurs couplés à la protéine g | |
IN2012DN00971A (fr) | ||
CL2008000690A1 (es) | Compuestos derivados del acido indol-3-propionico; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como hiperlipidemia, hipertension; entre otras. | |
WO2009126688A3 (fr) | Compositions et procédés nouveaux pour le traitement de maladies de nature immunitaire | |
EP2318033B8 (fr) | Compositions destinées au traitement de la douleur et/ou de l'inflammation | |
WO2006023852A3 (fr) | Modulateurs des recepteurs muscariniques | |
EP3578568A3 (fr) | Polypeptides se liant aux récepteurs de cxcr2 | |
WO2011038933A3 (fr) | Anticorps anti-vhs (virus de l'herpès simplex) | |
IL193479A0 (en) | Modulators of muscarinic receptors | |
WO2008021375A3 (fr) | Modulateurs de récepteurs muscariniques | |
WO2010116282A8 (fr) | Composés 4,5-dihydro-lh-pyrazole et leurs utilisations pharmaceutiques | |
WO2007106022A3 (fr) | Nouvelles formes cristallines | |
WO2010026168A3 (fr) | Substances et procédés pour le traitement de la sclérose en plaques véhiculée par les lymphocytes b | |
WO2012037116A3 (fr) | Variations génétiques communes et rares associées à une immunodéficience commune variable (icv) et procédés d'utilisation de celles-ci pour le traitement et le diagnostic de cet état | |
WO2006058303A3 (fr) | Modulateurs des recepteurs muscariniques | |
WO2012020108A3 (fr) | Inhibiteurs multimères de fusion virale et ses utilisations | |
WO2009156680A3 (fr) | Association d'un agoniste partiel des recepteurs nicotiniques et d'un inhibiteur d'acetylcholinesterase, composition pharmaceutique la contenant et son utilisation dans le traitement des troubles cognitifs | |
UA103468C2 (ru) | Соединения циклоалкилокси- и гетероциклоалкилоксипиридина как модуляторы гистаминового рецептора н3 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09782523 Country of ref document: EP Kind code of ref document: A2 |
|
DPE2 | Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2009782523 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009289280 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 591140 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2735085 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2009289280 Country of ref document: AU Date of ref document: 20090902 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2011525541 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011112857 Country of ref document: RU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13062115 Country of ref document: US |